Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in High-Risk Primary Membranous Nephropathy
NCT07163611Phase 3Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2025
- Primary completion
- Apr 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of obinutuzumab in primary membranous nephropathy (PMN), sponsored by Radboud University Medical Center. Primary endpoint: Disappearance rate (half-life) of anti-PLA2R antibodies at 52 weeks. Started Oct 2025; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT07163611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07163611.